Please login to the form below

Not currently logged in

Industry veteran Louis Nisbet joins Sygnature board

Brings experience from Roche, Glaxo and SmithKline

Sygnature Louis NisbetSygnature Discovery has appointed Dr Louis Nisbet to its board as a non-executive director.

The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

Following this period, he became an entrepreneur, helping to found companies such as Xenova, Brax and InTouch with Health.

Dr Nisbet's current roles include serving as venture partner with Kurma Life Sciences Partners and chairman of the science park BioCity in Nottingham, UK.

Sygnature's CEO Dr Simon Hirst commented that Dr Nisbet joins the board at a time of growth for the company, which includes the recent addition of in vitro bioscience to its capabilities and enhancing its computational chemistry and informatics capabilities.

“Louis will provide us with advice and guidance as we continue our expansion and evolution as a business,” said Dr Hirst.

1st October 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....